SCHEMBL6652022

SCHEMBL6652022

NC(=O)C1CC(=O)NC(=O)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
APEX1 P27695 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RGS12 O14924 1/20 0.37
TSHR P16473 1/20 0.37
CRBN Q96SW2 1/20 0.33
ITGB3 P05106 1/20 0.32
ITGB2 P05107 1/20 0.32
ITGB1 P05556 1/20 0.32
ITGAV P06756 1/20 0.32
ITGA2B P08514 1/20 0.32
ITGA5 P08648 1/20 0.32
ITGB5 P18084 1/20 0.32
ITGAL P20701 1/20 0.32
GLI1 P08151 1/20 0.31
MAP3K14 Q99558 1/20 0.31
CAD P27708 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27410036 0.84
SCHEMBL10638500 0.84
Dihydroorotate SCHEMBL121953 0.81 CAD (0.43) MEN1KMT2ATSHRCRBNITGB3
Dihydroorotate SCHEMBL758070 0.81 CAD (0.43) MEN1KMT2ATSHRCRBNITGB3
Dihydroorotate SCHEMBL29901858 0.81 CAD (0.43) MEN1KMT2ATSHRCRBNITGB3
Dihydroorotate SCHEMBL417324 0.81 CAD (0.43) MEN1KMT2ATSHRCRBNITGB3
SCHEMBL23182639 0.79 CRBN (0.38) L3MBTL1TSHRCRBNITGB3ITGB2
SCHEMBL14528005 0.79 CRBN (0.38) L3MBTL1TSHRCRBNITGB3ITGB2
SCHEMBL13219138 0.79 CRBN (0.38) L3MBTL1TSHRCRBNITGB3ITGB2
SCHEMBL29889995 0.79 RGS12 (0.34) RGS12TSHRCRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
EP-4384493-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2024-06-19 EP disclosed
CN-118076581-A Iron death modulators, their preparation and use 维泰瑞隆有限公司 2024-05-24 CN disclosed
WO-2023016447-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-02-16 WO disclosed
EP-4114375-A1 FERROPTOSIS INHIBITORS-DIARYLAMINE PARA-ACETAMIDES Sironax Ltd (KY) 2023-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS MEN1 1290/4885APEX1 3052/4885KMT2A 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.